PMCB
NASD PharmaCyte Biotech, Inc.$0.4001 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.4001, $0.0247 below the day’s high of $0.4248
- YTD change
- -44.74%
- vs 20-day SMA
- -9.04%
- vs 200-day SMA
- -42.26%
Price ranges
Price & Performance
-0.29 (-42.01%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 96.0% away from all-time highs of $10.0000
- PMCB is down 45% since the beginning of the year
- PMCB is down 60% over the past 12 months
- PMCB is down 17% over the past 1 month
- 1% of all PMCB investors are betting against PMCB
PMCB reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -60.4%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0080
- Last 5 days
- -12.34%
- vs 8-day SMA
- -6.89%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
